NCT04436029 · ADVERSE EVENTS

Adverse events

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy · Source last updated 2024-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Through study completion, median follow up 6 months with a range of 1-9 months
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Descartes 11 Descartes 11: CAR T cells	0 / 4	0 / 4	1 / 4

Group identifiers: EG000: Descartes 11

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
1
deaths Num At Risk
4
description
Descartes 11: CAR T cells
id
EG000
other Num Affected
0
other Num At Risk
4
serious Num Affected
0
serious Num At Risk
4
title
Descartes 11

frequency Threshold

time Frame

Through study completion, median follow up 6 months with a range of 1-9 months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice